Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Cash (2021 - 2025)

Historic Change in Cash for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Change in Cash rose 16450.02% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 19532.93%. This contributed to the annual value of -$20.2 million for FY2024, which is 8555.76% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Change in Cash of $8.0 million as of Q3 2025, which was up 16450.02% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Change in Cash registered a high of $173.2 million during Q4 2022, and its lowest value of -$122.7 million during Q1 2023.
  • Its 5-year average for Change in Cash is $1.8 million, with a median of -$7.6 million in 2022.
  • Data for ARS Pharmaceuticals' Change in Cash shows a peak YoY increase of 50891.19% (in 2023) and a maximum YoY decrease of 146170.1% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Change in Cash stood at $121.5 million in 2021, then surged by 42.61% to $173.2 million in 2022, then tumbled by 93.97% to $10.4 million in 2023, then grew by 6.91% to $11.2 million in 2024, then decreased by 28.16% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $11.7 million for Q2 2025, and -$11.0 million during Q1 2025.